Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

Category

Sub-category

Conference

CheckMate 9ER: aRCC patients on nivolumab plus cabozantinib achieved deeper...

Dr Cristina Suarez - Vall d’Hebron University Hospital, Catalonia, Spain

CheckMate 9ER: aRCC patients on nivolumab plus cabozantinib achieved deeper responses vs sunitinib ( Dr Cristina Suarez - Vall d’Hebron University Hospital, Catalonia, Spain )

Pancreatic neuroendocrine tumours: Capecitabine plus temozolomide gives longer...

Dr Pamela Kunz - Yale Cancer Center, New Haven, USA

Pancreatic neuroendocrine tumours: Capecitabine plus temozolomide gives longer PFS than temozolomide alone ( Dr Pamela Kunz - Yale Cancer Center, New Haven, USA )

ctDNA sequencing detects outcomes for pretreated advanced gastrointestinal...

Dr César Serrano - Vall d'Hebron Institute of Oncology, Barcelona, Spain

ctDNA sequencing detects outcomes for pretreated advanced gastrointestinal stromal tumour ( Dr César Serrano - Vall d'Hebron Institute of Oncology, Barcelona, Spain )

FOLFOXIRI plus panitumumab vs mFOLFOX6/PAN for unresectable RAS and BRAF wild...

Dr Chiara Cremolini - University of Pisa, Pisa, Italy

FOLFOXIRI plus panitumumab vs mFOLFOX6/PAN for unresectable RAS and BRAF wild-type mCC ( Dr Chiara Cremolini - University of Pisa, Pisa, Italy )

Comment: Panitumumab plus mFOLFOX6 improves OS for RAS wild-type left sided mCRC

Dr Chiara Cremolini - University of Pisa, Pisa, Italy

Comment: Panitumumab plus mFOLFOX6 improves OS for RAS wild-type left sided mCRC ( Dr Chiara Cremolini - University of Pisa, Pisa, Italy )

Can we afford the cost of newly approved targeted therapeutics in the...

Dr Sana Al Sukhun - Al Hyatt Oncology Practice, Amman

Can we afford the cost of newly approved targeted therapeutics in the management of breast cancer globally? ( Dr Sana Al Sukhun - Al Hyatt Oncology Practice, Amman )

Adjuvant endocrine therapy used to treat ER+ HER2- breast cancer

Dr Etienne Brain - Institut Curie, Paris, France

Adjuvant endocrine therapy used to treat ER+ HER2- breast cancer ( Dr Etienne Brain - Institut Curie, Paris, France )

Dabrafenib plus trametinib significantly increases overall response rate in...

Dr Eric Bouffet - The Hospital for Sick Children, Toronto, Canada

Dabrafenib plus trametinib significantly increases overall response rate in paediatric low-grade gliomas ( Dr Eric Bouffet - The Hospital for Sick Children, Toronto, Canada )

Comment: Dabrafenib plus trametinib significantly increases overall response...

Dr Melissa Hudson- St. Jude Children's Research Hospital, Memphis, USA

Comment: Dabrafenib plus trametinib significantly increases overall response rate in paediatric low-grade gliomas ( Dr Melissa Hudson- St. Jude Children's Research Hospital, Memphis, USA )

Dabrafenib plus trametinib significantly increases overall response rate in...

Dr Eric Bouffet - The Hospital for Sick Children, Toronto, Canada

Dabrafenib plus trametinib significantly increases overall response rate in paediatric low-grade gliomas ( Dr Eric Bouffet - The Hospital for Sick Children, Toronto, Canada )

ASCO 2022: Latest developments in mHSPC and mCRPC

Prof Heather Payne, Prof Kim Chi, Prof Laura-Maria Krabbe and Prof Kurt Miller

ASCO 2022: Latest developments in mHSPC and mCRPC ( Prof Heather Payne, Prof Kim Chi, Prof Laura-Maria Krabbe and Prof Kurt Miller )

COSMIC-021: Cabozantinib plus atezolizumab gives encouraging clinical activity...

Dr Sumanta K. Pal - City of Hope Comprehensive Cancer Center, Duarte, USA

COSMIC-021: Cabozantinib plus atezolizumab gives encouraging clinical activity in inoperable locally advanced/metastatic urothelial carcinoma ( Dr Sumanta K. Pal - City of Hope Comprehensive Cancer Center, Duarte, USA )

More from ecancer